Declared Dividend • May 04
Dividend increased to €12.00 Dividend of €12.00 is 20% higher than last year. Ex-date: 29th June 2026 Payment date: 1st July 2026 Dividend yield will be 1.5%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (25% earnings payout ratio) and cash flows (38% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 25% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Duyuru • Apr 28
Robertet SA, Annual General Meeting, Jun 03, 2026 Robertet SA, Annual General Meeting, Jun 03, 2026. Location: 48 avenue jean maubert, grasse France Reported Earnings • Apr 17
Full year 2025 earnings released Full year 2025 results: Revenue: €849.8m (up 5.2% from FY 2024). Net income: €103.4m (up 15% from FY 2024). Profit margin: 12% (up from 11% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 7.0% decline forecast for the Chemicals industry in the United Kingdom. Duyuru • Apr 11
Robertet SA Proposes Dividend for the Year 2025 Robertet SA announced the Annual General Meeting will be held on June 3, 2026 and the shareholders will be invited to approve a dividend payment of €12 per share, up 20% on the previous year owing to Robertet's strong results in 2025. Duyuru • Feb 12
Robertet SA to Report First Half, 2026 Final Results on Sep 21, 2026 Robertet SA announced that they will report first half, 2026 final results on Sep 21, 2026 Board Change • Jan 16
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 6 non-independent directors. Independent Director Lucie Maurel-Aubert was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Sep 12
Robertet SA to Report First Half, 2025 Final Results on Sep 18, 2025 Robertet SA announced that they will report first half, 2025 final results on Sep 18, 2025 Duyuru • Jul 25
Robertet SA to Report First Half, 2025 Results on Sep 11, 2025 Robertet SA announced that they will report first half, 2025 results on Sep 11, 2025 Upcoming Dividend • Jun 20
Upcoming dividend of €10.00 per share Eligible shareholders must have bought the stock before 27 June 2025. Payment date: 01 July 2025. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (5.6%). Lower than average of industry peers (4.1%). Duyuru • Apr 29
Robertet SA, Annual General Meeting, Jun 04, 2025 Robertet SA, Annual General Meeting, Jun 04, 2025. Location: 48 avenue jean maubert, grasse France Declared Dividend • Apr 28
Dividend increased to €10.00 Dividend of €10.00 is 18% higher than last year. Ex-date: 27th June 2025 Payment date: 1st July 2025 Dividend yield will be 1.2%, which is lower than the industry average of 3.0%. Duyuru • Nov 06
Robertet SA (ENXTPA:RBT) agreed to acquire Phasex Corporation. Robertet SA (ENXTPA:RBT) agreed to acquire Phasex Corporation on November 4, 2024. Reported Earnings • Sep 27
First half 2024 earnings released: EPS: €24.71 (vs €19.14 in 1H 2023) First half 2024 results: EPS: €24.71 (up from €19.14 in 1H 2023). Revenue: €414.6m (up 10% from 1H 2023). Net income: €51.7m (up 29% from 1H 2023). Profit margin: 13% (up from 11% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 5.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Board Change • Jun 06
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Lucie Maurel-Aubert was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 22
Full year 2023 earnings released: EPS: €35.71 (vs €32.85 in FY 2022) Full year 2023 results: EPS: €35.71. Revenue: €735.6m (up 4.6% from FY 2022). Net income: €74.6m (down 1.9% from FY 2022). Profit margin: 10% (in line with FY 2022). Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 2.4% decline forecast for the Chemicals industry in the United Kingdom. New Risk • Apr 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. Buy Or Sell Opportunity • Apr 09
Now 20% undervalued Over the last 90 days, the stock has risen 1.8% to €807. The fair value is estimated to be €1,011, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 12% per annum over the same time period. Buy Or Sell Opportunity • Feb 21
Now 22% undervalued Over the last 90 days, the stock has risen 4.5% to €794. The fair value is estimated to be €1,024, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 12% per annum over the same time period. Buy Or Sell Opportunity • Feb 21
Now 22% undervalued Over the last 90 days, the stock has risen 4.8% to €794. The fair value is estimated to be €1,022, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 12% per annum over the same time period. Reported Earnings • Oct 05
First half 2023 earnings released: EPS: €19.13 (vs €19.49 in 1H 2022) First half 2023 results: EPS: €19.13 (down from €19.49 in 1H 2022). Revenue: €376.4m (up 4.9% from 1H 2022). Net income: €39.9m (down 11% from 1H 2022). Profit margin: 11% (down from 13% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 5.1% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Upcoming Dividend • Jun 22
Upcoming dividend of €8.50 per share at 1.0% yield Eligible shareholders must have bought the stock before 29 June 2023. Payment date: 03 July 2023. Payout ratio is a comfortable 26% and the cash payout ratio is 77%. Trailing yield: 1.0%. Lower than top quartile of British dividend payers (5.9%). Lower than average of industry peers (2.8%). Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Director Elie Vannier was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • May 01
Full year 2021 earnings released Full year 2021 results: Revenue: €608.8m (up 13% from FY 2020). Net income: €71.7m (up 42% from FY 2020). Profit margin: 12% (up from 9.4% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 11% compared to a 16% decline forecast for the industry in the United Kingdom. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 01
First half 2021 earnings released: EPS €16.47 (vs €13.03 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €297.6m (up 6.2% from 1H 2020). Net income: €38.1m (up 27% from 1H 2020). Profit margin: 13% (up from 11% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 05
Full year 2020 earnings released: EPS €21.88 (vs €22.96 in FY 2019) The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €538.3m (down 2.9% from FY 2019). Net income: €50.6m (down 4.7% from FY 2019). Profit margin: 9.4% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Jan 29
New 90-day high: €955 The company is up 3.0% from its price of €923 on 30 October 2020. The British market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 20% over the same period. Is New 90 Day High Low • Dec 11
New 90-day low: €546 The company is down 45% from its price of €996 on 11 September 2020. The British market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period. Valuation Update With 7 Day Price Move • Dec 11
Investor sentiment deteriorated over the past week After last week's 38% share price decline to €546, the stock is trading at a trailing P/E ratio of 36.9x, down from the previous P/E ratio of 59.8x. This compares to an average P/E of 40x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 40%. Valuation Update With 7 Day Price Move • Dec 10
Market pulls back on stock over the past week After last week's 39% share price decline to €546, the stock is trading at a trailing P/E ratio of 36.9x, down from the previous P/E ratio of 60.7x. This compares to an average P/E of 40x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%. Valuation Update With 7 Day Price Move • Dec 07
Market pulls back on stock over the past week After last week's 40% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.3x, down from the previous P/E ratio of 63.4x. This compares to an average P/E of 39x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%. Valuation Update With 7 Day Price Move • Dec 03
Market pulls back on stock over the past week After last week's 39% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.7x, down from the previous P/E ratio of 63.2x. This compares to an average P/E of 39x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%. Valuation Update With 7 Day Price Move • Nov 30
Market pulls back on stock over the past week After last week's 39% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.7x, down from the previous P/E ratio of 63.8x. This compares to an average P/E of 38x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%. Valuation Update With 7 Day Price Move • Nov 27
Market pulls back on stock over the past week After last week's 40% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.7x, down from the previous P/E ratio of 64.1x. This compares to an average P/E of 37x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%. Valuation Update With 7 Day Price Move • Nov 24
Market pulls back on stock over the past week After last week's 42% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.5x, down from the previous P/E ratio of 66.8x. This compares to an average P/E of 40x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%. Is New 90 Day High Low • Nov 20
New 90-day low: €546 The company is down 39% from its price of €897 on 21 August 2020. The British market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period. Valuation Update With 7 Day Price Move • Nov 20
Market pulls back on stock over the past week After last week's 42% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.5x, down from the previous P/E ratio of 66.8x. This compares to an average P/E of 39x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%. Is New 90 Day High Low • Oct 12
New 90-day high: €1,036 The company is up 8.0% from its price of €958 on 13 July 2020. The British market is down 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 10.0% over the same period. Reported Earnings • Oct 02
First half earnings released Over the last 12 months the company has reported total profits of €53.7m, largely unchanged from the prior year. Total revenue was €547.4m over the last 12 months, up 1.0% from the prior year.